vs
Side-by-side financial comparison of DuPont (DD) and Solventum (SOLV). Click either name above to swap in a different company.
Solventum is the larger business by last-quarter revenue ($2.0B vs $1.7B, roughly 1.2× DuPont). DuPont runs the higher net margin — 9.8% vs 0.6%, a 9.1% gap on every dollar of revenue. On growth, DuPont posted the faster year-over-year revenue change (4.0% vs -3.0%). Over the past eight quarters, Solventum's revenue compounded faster (-1.8% CAGR vs -27.2%).
DuPont de Nemours, Inc., commonly shortened to DuPont, is an American multinational chemical company first formed in 1802 by French-American chemist and industrialist Éleuthère Irénée du Pont de Nemours. The company played a major role in the development of the U.S. state of Delaware and first arose as a major supplier of gunpowder.
Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024.
DD vs SOLV — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $2.0B |
| Net Profit | $164.0M | $13.0M |
| Gross Margin | 35.8% | 54.7% |
| Operating Margin | — | 4.0% |
| Net Margin | 9.8% | 0.6% |
| Revenue YoY | 4.0% | -3.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.36 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.7B | $2.0B | ||
| Q4 25 | $-2.5B | $2.0B | ||
| Q3 25 | $3.1B | $2.1B | ||
| Q2 25 | $3.3B | $2.2B | ||
| Q1 25 | $3.1B | $2.1B | ||
| Q4 24 | $3.1B | $2.1B | ||
| Q3 24 | $3.2B | $2.1B | ||
| Q2 24 | $3.2B | $2.1B |
| Q1 26 | $164.0M | $13.0M | ||
| Q4 25 | $-126.0M | $63.0M | ||
| Q3 25 | $-123.0M | $1.3B | ||
| Q2 25 | $59.0M | $90.0M | ||
| Q1 25 | $-589.0M | $137.0M | ||
| Q4 24 | $-118.0M | $31.0M | ||
| Q3 24 | $454.0M | $122.0M | ||
| Q2 24 | $178.0M | $89.0M |
| Q1 26 | 35.8% | 54.7% | ||
| Q4 25 | — | 51.4% | ||
| Q3 25 | 38.9% | 54.2% | ||
| Q2 25 | 37.3% | 54.4% | ||
| Q1 25 | 37.4% | 53.8% | ||
| Q4 24 | 36.4% | 53.9% | ||
| Q3 24 | 37.4% | 56.0% | ||
| Q2 24 | 37.1% | 54.6% |
| Q1 26 | — | 4.0% | ||
| Q4 25 | — | 6.3% | ||
| Q3 25 | 10.6% | 80.6% | ||
| Q2 25 | 9.4% | 9.9% | ||
| Q1 25 | -14.0% | 7.3% | ||
| Q4 24 | 1.4% | 6.6% | ||
| Q3 24 | 18.4% | 13.2% | ||
| Q2 24 | 9.3% | 11.7% |
| Q1 26 | 9.8% | 0.6% | ||
| Q4 25 | 4.9% | 3.2% | ||
| Q3 25 | -4.0% | 60.4% | ||
| Q2 25 | 1.8% | 4.2% | ||
| Q1 25 | -19.2% | 6.6% | ||
| Q4 24 | -3.8% | 1.5% | ||
| Q3 24 | 14.2% | 5.9% | ||
| Q2 24 | 5.6% | 4.3% |
| Q1 26 | $0.36 | $0.07 | ||
| Q4 25 | $-0.30 | $0.37 | ||
| Q3 25 | $-0.29 | $7.22 | ||
| Q2 25 | $0.14 | $0.51 | ||
| Q1 25 | $-1.41 | $0.78 | ||
| Q4 24 | $-0.28 | $0.18 | ||
| Q3 24 | $1.08 | $0.70 | ||
| Q2 24 | $0.42 | $0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $710.0M | $561.0M |
| Total DebtLower is stronger | $3.2B | $4.6B |
| Stockholders' EquityBook value | $14.2B | $5.0B |
| Total Assets | $21.4B | $14.1B |
| Debt / EquityLower = less leverage | 0.22× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $710.0M | $561.0M | ||
| Q4 25 | $715.0M | $878.0M | ||
| Q3 25 | $2.0B | $1.6B | ||
| Q2 25 | $1.8B | $492.0M | ||
| Q1 25 | $1.8B | $534.0M | ||
| Q4 24 | $1.9B | $762.0M | ||
| Q3 24 | $1.6B | $772.0M | ||
| Q2 24 | $1.5B | $897.0M |
| Q1 26 | $3.2B | $4.6B | ||
| Q4 25 | $3.1B | $5.0B | ||
| Q3 25 | $7.0B | $5.1B | ||
| Q2 25 | $5.3B | $7.8B | ||
| Q1 25 | $5.3B | $7.9B | ||
| Q4 24 | $5.3B | $8.0B | ||
| Q3 24 | $7.2B | $8.1B | ||
| Q2 24 | $7.2B | $8.3B |
| Q1 26 | $14.2B | $5.0B | ||
| Q4 25 | $13.9B | $5.0B | ||
| Q3 25 | $22.9B | $5.0B | ||
| Q2 25 | $23.1B | $3.6B | ||
| Q1 25 | $22.8B | $3.3B | ||
| Q4 24 | $23.4B | $3.0B | ||
| Q3 24 | $24.2B | $3.2B | ||
| Q2 24 | $23.3B | $2.9B |
| Q1 26 | $21.4B | $14.1B | ||
| Q4 25 | $21.6B | $14.3B | ||
| Q3 25 | $38.0B | $14.0B | ||
| Q2 25 | $36.6B | $15.1B | ||
| Q1 25 | $36.0B | $14.5B | ||
| Q4 24 | $36.6B | $14.5B | ||
| Q3 24 | $37.5B | $14.7B | ||
| Q2 24 | $36.6B | $14.6B |
| Q1 26 | 0.22× | 0.92× | ||
| Q4 25 | 0.23× | 1.00× | ||
| Q3 25 | 0.31× | 1.03× | ||
| Q2 25 | 0.23× | 2.14× | ||
| Q1 25 | 0.23× | 2.43× | ||
| Q4 24 | 0.23× | 2.71× | ||
| Q3 24 | 0.30× | 2.54× | ||
| Q2 24 | 0.31× | 2.90× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | — | $-273.0M |
| FCF MarginFCF / Revenue | — | -13.6% |
| Capex IntensityCapex / Revenue | 6.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-203.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-700.0M | $95.0M | ||
| Q3 25 | $497.0M | $76.0M | ||
| Q2 25 | $381.0M | $169.0M | ||
| Q1 25 | $382.0M | $29.0M | ||
| Q4 24 | $564.0M | $219.0M | ||
| Q3 24 | $737.0M | $169.0M | ||
| Q2 24 | $527.0M | $355.0M |
| Q1 26 | — | $-273.0M | ||
| Q4 25 | $-850.0M | $32.0M | ||
| Q3 25 | $379.0M | $-21.0M | ||
| Q2 25 | $265.0M | $59.0M | ||
| Q1 25 | $133.0M | $-80.0M | ||
| Q4 24 | $403.0M | $92.0M | ||
| Q3 24 | $628.0M | $76.0M | ||
| Q2 24 | $425.0M | $297.0M |
| Q1 26 | — | -13.6% | ||
| Q4 25 | 33.4% | 1.6% | ||
| Q3 25 | 12.3% | -1.0% | ||
| Q2 25 | 8.1% | 2.7% | ||
| Q1 25 | 4.3% | -3.9% | ||
| Q4 24 | 13.0% | 4.4% | ||
| Q3 24 | 19.7% | 3.7% | ||
| Q2 24 | 13.4% | 14.3% |
| Q1 26 | 6.1% | — | ||
| Q4 25 | -5.9% | 3.2% | ||
| Q3 25 | 3.8% | 4.6% | ||
| Q2 25 | 3.6% | 5.1% | ||
| Q1 25 | 8.1% | 5.3% | ||
| Q4 24 | 5.2% | 6.1% | ||
| Q3 24 | 3.4% | 4.5% | ||
| Q2 24 | 3.2% | 2.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.51× | ||
| Q3 25 | — | 0.06× | ||
| Q2 25 | 6.46× | 1.88× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | 7.06× | ||
| Q3 24 | 1.62× | 1.39× | ||
| Q2 24 | 2.96× | 3.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DD
Segment breakdown not available.
SOLV
| Infection Prevention and Surgical Solutions | $737.0M | 37% |
| Advanced Wound Care | $497.0M | 25% |
| Dental Solutions | $354.0M | 18% |
| Health Information Systems | $342.0M | 17% |
| All Other 4 | $76.0M | 4% |
